The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Geoffrey Thomas Gibney
Consultant or Advisory Role - Roche/Genentech
Maryna Marynchenko
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Philip J Galebach
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Charles Ayas
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Nathan S. Liu
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Eric Qiong Wu
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Yeun Mi Yim
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Sarang S. Abhyankar
Employment or Leadership Position - Roche/Genentech
Stock Ownership - Roche
Carolina M. Reyes
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Annie Guérin
Consultant or Advisory Role - Genentech
Research Funding - Genentech